Rituximab Objective Outcome Measures Trial in SLE (ROOTS)
A Feasibility Randomised Placebo-controlled Trial With Objective Outcome Measures to Evaluate the Efficacy of Biosimilar Rituximab in Musculoskeletal and Mucocutaneous Systemic Lupus Erythematosus
This is a feasibility study to test a new trial design for an important drug in Systemic Lupus Erythematosus (SLE or "lupus").
SLE is an autoimmune disease. The immune system attacks the body's own tissues, any part of the body may be affected, but most commonly lupus causes a rash and arthritis, this affects patients' quality of life.
Lupus is usually treated with steroids or drugs that suppress the immune system. Although these help, many patients don't respond well enough and there is also concern for long term side effects. There is a new type of treatment called biologics. These target individual cells or molecules rather than the whole immune system and may be more effective with fewer side-effects. B cells are a part of the immune system that are known to play a role in lupus. There is already a biologic that removes these, called rituximab. In rheumatoid arthritis and vasculitis (similar to lupus), rituximab has been proven to be effective in clinical trials. However, in lupus clinical trials it did not seem to show any benefit. But many doctors and patients found that rituximab is effective, but the trials couldn't show this because of the way the drug's effects were measured. Therefore it is important that we test whether it truly is effective for lupus.
In this 6 month clinical study the investigators will look at lupus patients who have skin disease and arthritis as these are very common and randomise them to receive either rituximab or a placebo. Patients will have a careful clinical examination and undergo different methods to measure the effectiveness of the treatment. There are new versions to rituximab called "biosimilars". In this study biosimilar GP2013 will be used.
If this trial is successful a larger definitive study will be designed based on its results.
調査の概要
研究の種類
入学 (予想される)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
West Yorkshire
-
Leeds、West Yorkshire、イギリス、LS7 4SA
- 募集
- Chapel Allerton Hospital- Leeds Institute for Rheumatic and Musculoskeletal Medicine
-
コンタクト：
- Edward Vital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged at least 18 years old
- Active musculoskeletal SLE defined by inflammatory musculoskeletal pain with either clinical synovitis, ultrasound tenosynovitis or positive power Doppler in at least 1 joint
- No contraindication to the use of IV methylprednisolone, biosimilar rituximab, or any other required medications such as antipyretics and antihistamines
- Willing to use appropriate contraception if at risk of pregnancy
- Disease activity that is refractory to hydroxychoroquine, or patients unable to take hydroxychoroquine due to contra-indication or prior toxicity
Exclusion Criteria:
• Severe "critical" SLE flare defined as: (i) BILAG 2004 A flare in CNS system; (ii) BILAG 2004 A flare in the renal system; or (iii) any other SLE manifestation requiring more immunosuppression than allowed within the protocol in the physician's opinion
- Pregnancy
- Breast Feeding
- Receipt of daily oral glucocorticoids greater than 10mg prednisolone or equivalent at screening or within the previous 5 days, or change in glucocorticoid dose in the previous 5 days.
- Receipt of intramuscular or intravenous glucocorticoids within the past 4 weeks
- Receipt of intravenous immunoglobulin, plasma exchange or cyclophosphamide within the last 3 months
- Rituximab within the past 18 months or other biologic therapies within the past 6 months
- Active infections, including but not limited to the human immunodeficiency virus, hepatitis B (including prior infection as judged by positive Hepatitis B core antibody) or hepatitis C
- Serum IgG below the lower limit of the local laboratory range
- Receipt of a live attenuated vaccine within 3 months prior to study enrolment
- History of cancer in the past 5 years except for squamous or basal cell carcinoma that has been completely excised or treated cervical carcinoma in situ
- In female participants, known history of cervical dysplasia CIN Grade III cervical high-risk human papillomavirus or abnormal cervical cytology other than abnormal squamous cells of undetermined significance (ASCUS) within the past 3 years. The patient will be eligible after the condition has resolved (e.g., follow-up HPV test is negative or cervical abnormality has been effectively treated >1 year ago)
- Planned surgery within the study period that is expected to require overnight hospital admission
- Any other concomitant medical condition that, in the investigator's opinion, or after discussion with the CI, places the participant at risk by participating in this study
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Intervention
2 x 1000mg Rituximab and 100mg methylprednisolone
|
1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
100mg infusion on days 1 and 15
250ml infusion on days 1 and 15
|
|
プラセボコンパレーター：Control
2 x 100mg methylprednisolone plus placebo
|
100mg infusion on days 1 and 15
250ml infusion on days 1 and 15
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility of trial considering adherence to protocol, completion of all assessments and visits
時間枠：26 weeks
|
Overall feasibility of the trial will be judged based on the feasibility variables.
It is acknowledged that this trial incorporates multiple inter-related aspects of design, with many possible modifications in trials derived from it.
Hence these numbers will be used as a guide only and specific target values have not been defined.
|
26 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients achieving BILAG-based Composite Lupus Assessment (BICLA)
時間枠：16 weeks
|
An assesment of clinical efficacy of treatment
|
16 weeks
|
|
Proportion of patients achieving SLEDAI responder Index (SRI)
時間枠：16 weeks
|
An assesment of clinical efficacy of treatment
|
16 weeks
|
|
Number of serious adverse events
時間枠：26 weeks
|
Safety assessment
|
26 weeks
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- RR15/197
- 2015-002688-40 (EudraCT番号)
- 16/YH/0032 (その他の識別子：Research Ethics Committee Reference Number)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Rituximabの臨床試験
-
Jiangsu HengRui Medicine Co., Ltd.まだ募集していません再発/耐衝撃性怠dolentNHL
-
University Hospital, Montpellierまだ募集していません
-
Peking Union Medical College Hospitalまだ募集していません
-
The First Affiliated Hospital with Nanjing Medical...募集